Pharma Marketing Network

There are several ways in which pharmaceutical companies or their agents can ADVERTISE products and ENGAGE in conversations via social networks. This survey asks repondents their opinions on best practices.

Which of five future scenarios -- Triumph of Reason, Big Brother Arrives, Consumer Chaos, Safety Net, PhRMA's Platform -- is likely to unfold in the next 10 years and which one would benefit the pharmaceutical industry the most?

Please take 2 minutes to answer this survey relating to pharma-sponsored medical journal article ghostwriting.

In the wake of the VIOXX withdrawal, critics have suggested that FDA needs to reform how it regulates the drug industry. Many suggestions for reform have been suggested. We present a few of them here. Let us know what you think of these suggestions or if the FDA requires no reform at all!

This survey asks you to express your opinion anonymously about FDA's letter to Novartis regarding its Tasigna Facebook Share button and other recent warnings sent to pharmaceutical companies, especially with regard to social media and search engine marketing.

This survey asked respondents to evaluate the pros and cons of marketing based on clinical evidence.

This survey collects comments regarding DTC issues discussed at a November 2005 FDA public hearing. These issues relating to the value of DTC advertising for consumers and pateints are as pertinent today as they were in 2005.

This survey collected comments regarding DTC issues discussed at a November 2005 FDA ipublic hearing.

Please take a few minutes to tell us your opinion of the future of Direct-to-Consumer (DTC) advertising of prescription medications under a new Democratic Administration.

This survey asks respondents questions relating to potential bias in continuing medical education (CME) programs supported by pharma/medical device companies and how to limit the need for industry funding of CME.